Neurotoxoplasmose e Neurocisticercose em Paciente com AIDS

relato de caso

Autores

  • Jossuel Carvalho Melo Martins Médico, Pós-graduando em Neurologia no Serviço de Neurologia do Hospital Universitário da Universidade Federal de Juiz de Fora-UFJF, Juiz de Fora- -MG, Brasil.
  • Marcelo Maroco Cruzeiro Médico Neurologista, Doutor, Professor adjunto III da Universidade Federal de Juiz de Fora-UFJF, Juiz de Fora-MG, Brasil.
  • Leopoldo Antônio Pires Médico Neurologista, Doutor, Professor adjunto IV, Coordenador da Pós- -Graduação e Residência Médica em Neurologia, Chefe do Serviço de Neurologia do Hospital Universitário da Universidade Federal de Juiz de Fora-UFJF, Juiz de Fora-MG, Brasil.

DOI:

https://doi.org/10.4181/RNC.2015.23.03.1043.08p

Palavras-chave:

Neurotoxoplasmose, Neurocisticercose, AIDS

Resumo

Objetivo. Relatar um caso de coinfecção por neurotoxoplasmose e neurocisticercose em mulher acometida pela AIDS. Método. Relato de caso prospectivo, descritivo e contemporâneo de paciente do sexo feminino, 36 anos, com quadro clínico compatível com síndrome de hipertensão intracraniana. Os exames complementares diagnostica­ram neurotoxoplasmose e a sorologia anti-HIV foi positiva. Evolui, após semanas, com crises convulsivas e exames subsidiários de imagem demonstrando neurocisticercose. Resultados. As infecções oportunis­tas relacionadas à AIDS são frequentes. A neurotoxoplasmose é cau­sada pelo protozoário Toxoplasma gondii e principal causa de lesão intracraniana expansiva em pacientes com AIDS. A neurocisticercose, provocada por cisticercos (Cysticercus cellulosae ou C. racemosus), formas larvárias da Taenia solium, é bastante prevalente em nosso meio. Conclusão. Após suspeição clínico-radiológica de neurotoxo­plasmose, torna-se imperativo realização de teste anti-HIV, devido sua elevada frequência neste grupo de pacientes. Já a comorbidade neurocisticercose e AIDS é achado excepcional, resultado mais prova­velmente de mera coincidência, sem qualquer vínculo predisponente entre si.

Métricas

Carregando Métricas ...

Referências

San-Andres FJ, Rubio R, Castilla JO, Pulido F, Palao G, de Pedro I, et al. Incidence of acquired immunodeficiency syndrome associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003;36:1177- 88. http://dx.doi.org/10.1086/374358

Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001;56:257-60. http://dx.doi.org/10.1212/ WNL. 56. 2. 257

Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4):1-207.

Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000;355:2217-8. http://dx.doi.org/10.1016/S0140-6736(00)02407-7

Flust O, French AL, Seaberg EC, Tien PC, Watts DH, Minkoff H, et al. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis 2002;35:1414- 7. http://dx.doi.org/10.1086/344462

Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. J Infect 2002;34:103-15. http://dx.doi.org/10.1086/324350

Skiest DJ, Erdman WC, Chang WE, Oz OK, Ware A, Fleckenstein J. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000;40:274-81. http://dx.doi.org/10.1053/jinf.2000.0664

Nath A, Sinai AP. Cerebral Toxoplasmosis. Curr Treat Options Neurol 2003;5:3-12.

Mesquita RT, Ziegler AP, Hiramoto RM, Vidal JE, Pereira-Chioccola VL. Real-time quantitative PCR in cerebral toxoplasmosis diagnosis of Brazilian human immunodeficiency virus-infected patients. J Med Microbiol 2010;59:641-7. http://dx.doi.org/10.1099/jmm.0.016261-0

Borges AS, Figueiredo JF. Detecção de Imunoglobulinas IgG, IgM e IgA Anti-Toxoplasma Gondii no Soro, Líquor e Saliva de Pacientes com Síndrome da Imunodeficiência Adquirida e Neurotoxoplasmose. Arq Neuropsiquiatr 2004;62:1033-7. http://dx.doi.org/10.1590/S0004-282X2004000600019

Nelson M, Dockrell D, Edwards S, Angus B, Barton S, Beeching N, et al. Subcommittee on behalf of the BG. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV seropositive individuals 2011. HIV Med 2011;12(Suppl 2):1-140. http://dx.doi.org/10.1111/j.14681293.2011.00944_1.x

Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, Bosler EM, et al. Dose escalation, phase 1/11 study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS 2001;15:583-9.

Masur H, Kaplan JE, Holmes KK; U.S. Public Health Service; Infectious Diseases Society of America. Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002;137:435-78.

Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. New Engl J Med 2000;342:1416-29. http://dx.doi.org/10.1056/NEJM200005113421907

Mussini C, Pezzotti, Govoni A, Borghi V, Antinori A, d’Arminio Monforte A, et al. Discontinuation of primary prophylaxis for Pneurnocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus

type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000;181:1635-42. http://dx.doi.org/ 10.1086/315471

Guex AC, Radziwill AJ, Bucher HC. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Clin Infect Dis 2000;30:602-3. http://dx.doi.org/10.1086/313733

Chirgwin K, Hafner R, Leport C, Remington J, Andersen J, Bosler EM, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA. Essai/039. Clin Infect Dis 2002;34:1243-50.

Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Data-base Syst Rev 2006;3:CD005420. http://dx.doi.org/10.1002/14651858.CD005420.pub2

White AC Jr. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Ann Rev Med 2000;51:187-206. http://dx.doi.org/10.1146/annurev.med.51.1.187

Costa-Cruz JM, Rocha A, Silva AM, De Moraes AT, Guimaraes AH, Salomao EC, et al. Occurrence of cysticercosis in autopsies performed in Uberlandia, Minas Gerais, Brazil. Arq Neuropsiquiatr 1995;53:227-32. http://dx.doi.org/10.1590/S0004-282X1995000200007

Carpio A, Placencia M, Santillan F, Escobar A. A proposal for classification of neurocysticercosis. Can J Neurol Sci 1994;21:43-7.

Machado LR, Nobrega JP, Barros NG, Livramento JA, Bacheschi LA, Spina-Franca A. Computed tomography in neurocysticercosis: a 10-year long evolution analysis of 100 patients with an appraisal of a new classification. Arq Neuropsiquiatr 1990;48:414-8. http://dx.doi.org/10.1590/S0004-282X1990000400003

Takayanagui OM, Lanchote VL, Marques MP, Bonato PS. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Therap Drug Monit 1997;19:51-5.

Cruz M, Cruz I, Horton J. Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation. Trans Royal Soc Trop Med Hyg 1991;85:244-7. http://dx.doi.org/10.1016/0035-9203(91)90041-V

Takayanagui OM, Jardim E. Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arc Neurol 1992;49:290-4. http://dx.doi.org/10.1001/archneur.1992.00530270106026

Sotelo J, del Brutto OH, Penagos P, Escobedo F, Torres B, Rodriguez- -Carbajal J, et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990;237:69-72. http://dx.doi.org/10.1007/BF00314663

Carpio A, Santillan F, Leon P, Flores C, Hauser WA. Is the course of neurocysticercosis modified by treatment with antihelminthic agentes. Arch Inter Med 1995;155:1982-8. http://dx.doi.org/10.1001/archinte.1995.00430180088010

Carpio A, Escobar A, Hauser WA. Cysticercosis and epilepsy: a critical review. Epilepsia 1998;39:1025-40. 29.Del Brutto OH. Neurocysticercosis actualizacion en diagnostico y tratamiento. Neurologia 2005;20:412-8.

Clemente HAM, Werneck ALS. Neurocisticercose: Incidência no Estado do Rio de Janeiro. Arq Neuropsiquiatr 1990;48:207-9. http://dx.doi.org/10.1590/S0004-282X1990000200012

Downloads

Publicado

2015-09-30

Como Citar

Martins, J. C. M., Cruzeiro, M. M., & Pires, L. A. (2015). Neurotoxoplasmose e Neurocisticercose em Paciente com AIDS: relato de caso. Revista Neurociências, 23(3), 443–450. https://doi.org/10.4181/RNC.2015.23.03.1043.08p

Edição

Seção

Relato de Caso
##plugins.generic.dates.received## 2019-02-12
##plugins.generic.dates.published## 2015-09-30

Artigos mais lidos pelo mesmo(s) autor(es)

Obs .: Este plugin requer que pelo menos um plugin de estatísticas / relatório esteja ativado. Se seus plugins de estatísticas fornecerem mais de uma métrica, selecione também uma métrica principal na página de configurações do site do administrador e / ou nas páginas de configurações do gerente da revista.

Artigos Semelhantes

1 2 > >> 

Você também pode iniciar uma pesquisa avançada por similaridade para este artigo.